Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Budget impact analysis: comparing the costs of nusinersen and risdiplam in the treatment of type 3 spinal muscular atrophy patients.
Eur J Hosp Pharm. 2023 Oct 28:ejhpharm-2023-003733. doi: 10.1136/ejhpharm-2023-003733. Online ahead of print.
Eur J Hosp Pharm. 2023.
PMID: 37898509
Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.
Degli Esposti L, Piccinni C, Sangiorgi D, Perrone V, Aledda L, Marrosu MG, Lombardo F.
Degli Esposti L, et al. Among authors: aledda l.
Neurol Sci. 2017 Apr;38(4):589-594. doi: 10.1007/s10072-016-2806-4. Epub 2017 Jan 11.
Neurol Sci. 2017.
PMID: 28078563
Item in Clipboard
Cite
Cite